APA (7th ed.) Citation

Wu, Y., Amonkar, M. M., Sherrill, B. H., O'Shaughnessy, J., Ellis, C., Baselga, J., . . . Burstein, H. J. (2019). Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Annals of Oncology, 30(6), 1019. https://doi.org/10.1093/annonc/mdy531

Chicago Style (17th ed.) Citation

Wu, Y., M M. Amonkar, B H. Sherrill, J. O'Shaughnessy, C. Ellis, J. Baselga, K L. Blackwell, and H J. Burstein. "Impact of Lapatinib Plus Trastuzumab Versus Single-agent Lapatinib on Quality of Life of Patients with Trastuzumab-refractory HER2+ Metastatic Breast Cancer." Annals of Oncology 30, no. 6 (2019): 1019. https://doi.org/10.1093/annonc/mdy531.

MLA (9th ed.) Citation

Wu, Y., et al. "Impact of Lapatinib Plus Trastuzumab Versus Single-agent Lapatinib on Quality of Life of Patients with Trastuzumab-refractory HER2+ Metastatic Breast Cancer." Annals of Oncology, vol. 30, no. 6, 2019, p. 1019, https://doi.org/10.1093/annonc/mdy531.